Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.

International journal of cancer - 15 Aug 2020

Ramraj Satish K, Elayapillai Sugantha P, Pelikan Richard C, Zhao Yan D, Isingizwe Zitha R, Kennedy Amy L, Lightfoot Stanley A, Benbrook Doris M

Abstract excerpt

Current ovarian cancer maintenance therapy is limited by toxicity and no proven impact on overall survival. To study a maintenance strategy targeted at missense mutant p53, we hypothesized that the release of mutant p53 from mortalin inhibition by the SHetA2 drug combined with reactivation of mutant p53 with the PRIMA-1MET drug inhibits growth and tumor establishment synergistically in a mutant-p53 dependent...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aza Compounds
Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromans

Share to HSP70 Heat-Shock Proteins

Share to Maintenance Chemotherapy

Share to Mice, Nude

Share to Molecular Targeted Therapy

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 31845320
DOI: 10.1002/ijc.32830
PMCID: PMC7297651

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.PMID 31845320Read ↗

Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancersSemantic proximity Read ↗

Why is Mortalin a Potential Therapeutic Target for Cancer?Semantic proximity Read ↗

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial TherapiesSemantic proximity Read ↗

The Challenges and Prospects of p53-Based Therapies in Ovarian Cancer.Semantic proximity Read ↗

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.Semantic proximity Read ↗

Targeted therapies: SOLO2 confirms olaparib maintenance in ovarian cancer.Semantic proximity Read ↗

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer.Semantic proximity Read ↗

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.Semantic proximity Read ↗

PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.Semantic proximity Read ↗

PRIMA-1MET induces death in soft-tissue sarcomas cell independent of p53Semantic proximity Read ↗

TP53 hot spot mutations in ovarian cancer: selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas.Semantic proximity Read ↗

Rescue of p53 functions by in vitro‐transcribed mRNA impedes the growth of high‐grade serous ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.